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Abstract
Background—Hepatitis B vaccine administered shortly after birth is highly effective in 
preventing mother to child transmission (MTCT) of infection. While hepatitis B vaccine was 
introduced in Haiti as part of a combined pentavalent vaccine in 2012, a birth dose is not yet 
included in the immunization schedule.
Objectives—Determine the seroprevalence of hepatitis B virus (HBV) infection among pregnant 
women to evaluate the risk of MTCT.
Study design—We selected 1364 residual serum specimens collected during a 2012 human 
immunodeficiency virus (HIV) sentinel serosurvey among pregnant women attending antenatal 
care clinics. Haiti was stratified into two regions: West, which includes metropolitan Port-au-
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Prince, and non-West, which includes all other departments. We evaluated the association between 
demographic and socioeconomic characteristics and HIV infection with HBV infection.
Results—Of 1364 selected specimens, 1307 (96%) were available for testing. A total of 422 
specimens (32.7%) tested positive for total anti-HBc (38.2% in West vs. 27% in non-West, p < 
0.001), and 33 specimens (2.5%) were HBsAg positive (2.1% in West vs. 3% in non-West, p = 
0.4). Of HBsAg positive specimens, 79% had detectable HBV DNA. Women aged 30 and older 
had more than double the odds of positive total anti-HBc than women aged 15–19 years (p < 
0.001). Women with secondary (adjusted odds ratio (aOR) = 0.54; 95% CI: 0.36–0.81) and post-
secondary education (aOR = 0.40, 95% CI: 0.19–0.79) had lower odds of total anti-HBc positivity 
compared with women with no education. HIV-status was not associated with HBV infection.
Conclusions—Haiti has an intermediate endemicity of chronic HBV infection with high 
prevalence of positive HBV DNA among chronically infected women. Introduction of a universal 
birth dose of hepatitis B vaccine might help prevent perinatal HBV transmission.
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1. Background
Hepatitis B virus (HBV) infection is a leading cause of morbidity and mortality due to 
hepatocellular carcinoma and liver cirrhosis worldwide. In the absence of vaccination, more 
than 50% of infection is attributable to infection during childhood and adolescence, and 
more than 20% of HBV-related deaths are attributable to perinatal infection [1,2]. The risk 
of progression to chronic infection is inversely related to the age of acquisition of infection; 
chronic infection develops in 80–90% of infants infected in the first year of life; this risk 
declines to 30–50% for children infected between 1 and 4 years of age [2].
In October 2012, Haiti became the last country in the Americas to introduce hepatitis B 
vaccine. The vaccine is provided at 6, 10, and 14 weeks of age, and is given as part of a 
combined pentavalent vaccine that protects against diphtheria, pertussis, tetanus, 
Hemophilus influenza type b (Hib) and hepatitis B. Despite recommendations by the World 
Health Organization (WHO) [2], a birth dose of hepatitis B vaccine is not included in the 
present vaccination schedule in Haiti. While childhood vaccination is effective in preventing 
horizontal HBV infection, it does not prevent perinatal transmission. In addition, pregnant 
women in Haiti are not routinely screened for HBV infection.
Since 2012, the Pan American Health Organization (PAHO) has been in the process of 
developing a regional strategy to address viral hepatitis. One of the components of this 
strategy is to establish baseline country estimates of the burden of hepatitis. Data on the 
hepatitis B disease burden in Haiti are outdated and limited. A study conducted in 2006 
among pregnant women reported an overall seroprevalence of hepatitis B surface antigen 
(HBsAg) of 5% with wide variations ranging from 1.0% to 8.5%, depending on the 
sampling clinic [3]. However, no data were available on hepatitis B envelope antigen 
(HBeAg) or HBV DNA levels which are important predictors for risk of mother to child 
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transmission (MTCT) of hepatitis B. Small studies conducted in the 1980s and among 
Haitian immigrants in the United States and Canada reported almost 50% prevalence of total 
antibody to hepatitis B core antigen (total anti-HBc) and a prevalence of HBsAg varying 
from 4% to 6% [4–7], indicating past or present infection. In a review of the 2013 blood 
donation screening data from the national blood transfusion program in Haiti, the prevalence 
of HBsAg was 3.5% with wide variability by department (2–8%) (Ernst Noel, personal 
communication).
2. Objectives
We conducted this study among pregnant women to assess the seroprevalence of HBV 
infection in this population and subsequent risk of MTCT. These results are essential to 
build evidence for introduction of a hepatitis B vaccine birth dose in Haiti.
3. Study design
3.1. Sample selection
We selected 1364 specimens from 6241 de-linked, residual serum specimens collected for 
the 2012 Biannual Sentinel Serosurvey for HIV among Pregnant Women. In summary, the 
sentinel HIV serosurvey included 18 antenatal care (ANC) sites, which were chosen to be 
geographically representative, with at least one site selected per department and representing 
urban and rural areas (Fig. 1). The ANC sites provide services for the prevention of MTCT 
of HIV.
Haiti is divided into 10 departments including Metropolitan Port-au-Prince. For this survey, 
we stratified Haiti into 2 regions: (1) the West region which includes the Ouest department 
along with metropolitan Port-au-Prince, and houses almost one third of the Haitian 
population, and (2) the non-West region which includes the remaining nine departments 
(Nord, Nord-Est, Nord-Ouest, Artibonite, Centre, Sud-Est, Sud, Nippes, Grande Anse). All 
164HIV-positive samples from the total sample of 6241 specimens were included in this 
study to test for co-infection rates for hepatitis B and HIV. For the HIV negative specimens, 
we randomly selected 600 specimens in each region by using an expected HBsAg 
prevalence of 5%, a desired precision of 2%, a 95% probability of achieving that precision, a 
design effect of 1.1 and an estimated 15% inadequate specimens. Age, education level, 
marital status, and job status information were available for each selected specimen. 
Education level was classified as no education (never entered school), primary (1–8 years of 
school), secondary (9–12 years of school), and post-secondary (any school years after 
secondary). The protocol was approved by the Haiti national bioethics committee and by the 
CDC human subject research office.
3.2. Laboratory testing
All specimens were first tested for total anti-HBc. If total anti-HBc was positive, then 
specimens were tested for HBsAg. Serology for hepatitis B markers was performed on an 
automated platform using chemiluminescent immunoassays (VITROS ECi, Ortho Clinical 
Diagnostics, Rochester, NY). Samples positive for HBsAg were tested for HBV DNA by in-
house quantitative PCR assays as previously described in Ref. [8]. Briefly, total nucleic acids 
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(TNA) were extracted using 200 µL of serum with the Roche MagNA Pure Isolation Kit I 
(Roche Applied Science, Rochester, NY) with a final elution volume of 50 µL followed by 
Taqman quantitative PCR (qPCR) for HBV DNA. The limit of detection of HBV DNA by 
PCR was 50 IU/mL.
3.3. Statistical analysis
We adjusted for weights considering the selection probability in each region and the non-
response rate based on site and HIV status. Seroprevalence of HBV infection was estimated 
by demographic and socio-economic characteristics for each region. We compared results 
for West vs. non-West region using p-values based on chi-square tests for homogeneity. In 
addition, we evaluated the association between demographic and socio-economic 
characteristics and HIV status with HBsAg and total anti-HBc in each region using chi-
square tests for independence to evaluate the effects of covariates. A multivariable logistic 
regression model was fit to assess the factors associated with total anti-HBc positivity. All 
reported percentages are weighted. Analysis was conducted using the statistical software R 
v. 3.0.2.
4. Results
Of the 1200 HIV-negative and 164 HIV-positive selected serum specimens, 1184 (98.7%) 
and 123 (75%) had enough volume to be tested for all markers, respectively. Therefore a 
total of 1307 specimens (634 in West and 673 in non-West region) were tested for 
seromarkers of HBV infection. More women completed secondary and higher education in 
the West compared with non-West region (p < 0.001), and there were more HIV-positive 
women in the non-West (12.6%) compared with the West region (6%) (p < 0.001) (Table 1).
Of the 1307 tested women, 422 (32.7%, 95% CI: 29.2–36.2) were total anti-HBc positive. 
Anti-HBc prevalence was higher in the non-West compared with West region (38.2%, 95% 
CI: 34.5–41.9 vs. 27.0%, 95% CI: 23.5–30.4; p < 0.001). Overall 33 women (2.5%, 95% CI: 
1.7–3.4) were positive for HBsAg, with 13 women (2.1%, 95% CI: 1.0–3.2) and 20 women 
(3.0%, 95% CI: 1.7–4.3) testing HBsAg positive in the West and non-West region, 
respectively (Table 2).
The prevalence of HBsAg generally increased with age from 2.7% among women aged 15–
19 years to 6.7% among those aged 40 and older, but this did not reach statistical 
significance (Table 2). Total anti-HBc prevalence increased with age ranging from 21% to 
50% (p < 0.001). Similarly, HBsAg and total anti-HBc seroprevalence decreased with higher 
educational level but the decrease was only significant for total anti-HBc (Table 2). HIV-
positive women had higher prevalence of positive total anti-HBc than HIV-negative women 
(44% vs. 32%, p = 0.006), but a similar HBsAg prevalence [2.4% (3/123)] as HIV-negative 
women [2.5% (30/1184)]. None of the HIV-positive women in the West region were HBsAg 
positive while three women were co-infected with HBV in the non-West region.
Among the 33HBsAg positive women, 26 (79%; 85% in West region, 75% in non-West 
region) had detectable HBV DNA levels: six had HBV DNA <1000 IU/mL, five had HBV 
DNA = 1000–4999 IU/mL, and 15 (46%; 46% in West region, 45% in non-West region) had 
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HBV DNA levels ≥5000 IU/mL. Nine HBsAg positive women had HBV DNA levels 
>200,000 IU/mL, among whom one was HIV-positive.
After adjusting for all covariates, the risk of anti-HBc positivity increased with age; women 
older than 30 years had more than double the odds of being total anti-HBc positive than 
those aged 15–19 years (Table 3). Women with secondary and post-secondary education had 
46% and 60% lower odds for total anti-HBc positivity compared to those with no education, 
respectively. Women who were not married had 1.4 times higher odds for total anti-HBc 
positivity compared with married women (p = 0.04). Job status and HIV-status were not 
associated with total anti-HBc positivity after controlling for the other variables.
5. Discussion and conclusions
This study is the first to assess the prevalence of HBV infection and measure HBV DNA 
levels among pregnant women in Haiti. We found that 2.5% of pregnant women were 
HBsAg positive, of whom about three-fourths had detectable HBV DNA, including almost 
half with HBV DNA levels ≥5000 IU/mL, and about a quarter with HBV DNA levels 
>200,000 IU/mL. HBV DNA levels are the most important predictors of MTCT of HBV 
infection [9–12]. These findings highlight the need for an introduction of a hepatitis B birth 
dose to prevent MTCT of HBV infection in Haiti.
Based on findings in this serosurvey and using the model developed by Goldstein et al., 
introduction of a hepatitis B birth dose with an assumption of achieving hepatitis B vaccine 
birth dose coverage within the range of 50–80% could prevent 38–61% of perinatal 
infections and HBV-related deaths due to perinatal infection in Haiti [13]. In 2012, PAHO 
recommended introduction of a hepatitis B vaccine birth dose in all countries in the 
Americas [14]. As of 2013, only 17 of 35 (48%) member states of PAHO have introduced a 
hepatitis B vaccine birth dose in the routine immunization schedule [15].
Given that Haiti is a low-income country with an intermediate endemicity of chronic HBV 
infection defined as a population HBsAg prevalence of 2–7% [2], the most operational 
intervention for prevention of perinatal HBV transmission would be universal introduction 
of hepatitis B vaccine within 24 h of birth without screening of pregnant women [16–19]. 
With Haiti’s limited resources and weak infrastructure, it might not be feasible or cost-
effective to screen all pregnant women for HBsAg or to include hepatitis B immunoglobulin 
(HBIG) in the prophylaxis protocol. In addition, infants who need post-exposure prophylaxis 
at birth might be missed with a targeted vaccination strategy. For example, in Greenland, a 
high proportion of infants born to HBsAg positive mothers did not receive hepatitis B 
vaccine at birth, and were not followed up after birth as a result of healthcare staff turnover 
and administrative failures to screen all pregnant women [20].
Introduction of a hepatitis B vaccine birth dose is most feasible when deliveries occur in 
healthcare settings. This is not the case in Haiti where only 36% of deliveries occur in a 
healthcare setting [21]. However, experience from countries in the Western Pacific Region 
(WPR), which had a high prevalence of chronic HBV infection prior to hepatitis B vaccine 
introduction, and where delivery in healthcare settings is also low, suggests that it is feasible 
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to successfully introduce a birth dose of hepatitis B vaccine in home-delivery settings [22]. 
Innovative interventions to increase birth dose coverage have been implemented in WPR 
countries, including promoting facility-based deliveries in conjunction with birth dose 
introduction, which helped improve timely birth dose administration and prevented perinatal 
infections. Promotion of facility-based delivery also contributed to decreasing maternal and 
neonatal mortality to meet the millennium development goals 4 and 5. In addition, home 
birth attendants were trained on vaccine administration and reporting so that infants 
delivered at home receive the birth dose in a timely manner [22,23]. Availability of good 
microplans was essential for successful administration of the birth dose at home [23]. 
Moreover, the use of monovalent hepatitis B vaccine in a controlled-temperature-chain 
(outside of the cold chain) and availability of Uniject could facilitate the logistics of using 
this vaccine in home-settings [22,24–27]. Although not currently licensed or pre-qualified 
for this use, several studies have demonstrated that hepatitis B vaccine can be kept up to one 
month in a controlled-temperature chain at temperatures up to 37 °C without losing its 
potency [25,26]. Testing the effectiveness of using the vaccine in a controlled-temperature 
chain in Haiti would help inform policy makers and perhaps facilitate the introduction of this 
strategy.
The prevalence of chronic HBV infection in Haiti among pregnant women has decreased 
compared to previous years. Prevalence in 2012 was half the prevalence reported in 2006 in 
the same population [3]. The prevalence of total anti-HBc in younger age groups was lower 
than among older women in 2012. In addition, unlike studies in the United States, Europe, 
and Ghana, which reported higher prevalence of chronic HBV infection among HIV-infected 
patients [28–32], we did not find a significant association between HIV and HBV infection 
in this study which is similar to findings reported among pregnant women in Uganda, 
Cameroon, and India [33–35]. Given that HIV and HBV have similar modes of transmission, 
preventive interventions targeting HIV infection, such as HIV counseling, testing, and 
treatment services available at those ANC site, and screening of blood for HIV and hepatitis 
B in Haiti, might have led to the decrease in HBV infection rates among pregnant women in 
Haiti [36,37].
This study has three main limitations. First, results cannot be generalized to the Haitian 
population as findings are only applicable to pregnant women with access to prenatal 
healthcare. According to the Demographic and Health Survey (DHS) conducted in 2012, 
90% of women who were pregnant received prenatal care which makes our results 
generalizable to pregnant women in Haiti [21]. Second, we were unable to determine the risk 
factors for HBV infection among pregnant women given that the sentinel serosurvey of 
pregnant women did not collect data on risk factors. However, it would be difficult to assess 
hepatitis B risk factors by self-reporting as infection could have occurred several years prior. 
Finally, we had a small sample of HBsAg positive women, which might have contributed to 
the inability to identify factors significantly associated with HBsAg positivity among 
pregnant women in Haiti.
In conclusion, Haiti has an intermediate endemicity for chronic HBV infection and the 
prevalence of chronic HBV infection among pregnant women has been decreasing over time. 
However, the high prevalence of elevated viral loads among pregnant women with chronic 
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infection indicates the potential high risk of MTCT of HBV. The introduction of pentavalent 
vaccine in 2012, and future addition of hepatitis B vaccination at birth could further help 
decrease childhood and perinatal HBV infection. However, ensuring access to the hepatitis B 
birth dose and achieving good vaccination coverage with all doses of hepatitis B-containing 
vaccines are essential. Serosurveys for HBV infection among children are needed to provide 
additional data to support the introduction of a hepatitis B birth dose in Haiti.
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Fig. 1. 
Distribution of the hospitals included in the antenatal care clinic serosurvey—Haiti, 2012.
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Table 3
Factors associated with anti-HBc positivity among pregnant women attending ante-natal care clinics—Haiti, 
2012.
Characteristics Total anti-HBc positive
Adjusted OR 95% CI p-value
Age (years)
15–19 1.00 –
20–24 1.58 1.03–2.45 0.03
25–29 1.71 1.11–2.68 0.01
30–34 2.43 1.53–3.91 <0.001
35–39 3.26 1.94–5.53 <0.001
≥40 2.77 1.33–5.75 0.006
Education level
None 1.00 –
Primary 0.73 0.48–1.10 0.1
Secondary 0.54 0.36–0.81 0.003
Post-secondary 0.40 0.19–0.79 0.01
Marital status
Married 1.00
Not-married 1.37 1.01–1.87 0.04
Job status
Employed 1.00 –
Unemployed 0.91 0.70–1.17 0.4
HIV status
Negative 1.00 –
Positive 1.37 0.92–2.02 0.1
95% CI: 95% confidence interval; analysis was adjusted for all variables in this table.
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